Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512855 | 1.00 | DHODH (0.37) | DHODHARS1PR1S1PR3S1PR5 | |
| SCHEMBL21463047 | 1.00 | DHODH (0.37) | DHODHARS1PR1S1PR3S1PR5 | |
| SCHEMBL20107645 | 0.90 | AR (0.35) | DHODHARCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29816586 | 0.90 | AR (0.35) | DHODHARCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL27175735 | 0.87 | DHODH (0.35) | DHODH | |
| SCHEMBL31134779 | 0.84 | CYP11B1 (0.42) | ARCYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL20108194 | 0.81 | AAK1 (0.40) | ARS1PR1S1PR3S1PR5CYP2D6 | |
| SCHEMBL29512830 | 0.81 | AAK1 (0.40) | ARS1PR1S1PR3S1PR5CYP2D6 | |
| SCHEMBL28696334 | 0.81 | AAK1 (0.40) | ARS1PR1S1PR3S1PR5CYP2D6 | |
| SCHEMBL1797074 | 0.78 | AAK1 (0.45) | ARS1PR1S1PR3S1PR5SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553052-A1 | 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer AG (DE) | 2019-10-16 | — | — | EP | disclosed |
| EP-3553052-A1 | 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer AG (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | Bayer Pharma AG (DE) | 2019-10-10 | — | — | US | disclosed |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | Bayer Pharma AG (DE) | 2019-10-10 | — | — | US | disclosed |
| WO-2018077944-A2 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018077923-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DPYD, DHPS | DHODH 1/4885AR 3879/4885S1PR1 2306/4885 |
| US-20190307728-A1 | METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | IDH3A, IDH3B, IDH2 | DHODH 161/4885AR 2359/4885S1PR1 3832/4885 |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | DHODH 1/4885AR 3937/4885S1PR1 2448/4885 |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | DHODH 1551/4885AR 2167/4885S1PR1 1717/4885 |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | DHODH 1/4885AR 2165/4885S1PR1 2703/4885 |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DHPS, DPYD | DHODH 1/4885AR 3937/4885S1PR1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.